1. Home
  2. ACR vs CGEN Comparison

ACR vs CGEN Comparison

Compare ACR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$23.76

Market Cap

143.3M

Sector

Real Estate

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.49

Market Cap

143.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
CGEN
Founded
2005
1993
Country
United States
Israel
Employees
N/A
74
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.3M
143.1M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
ACR
CGEN
Price
$23.76
$1.49
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$24.50
N/A
AVG Volume (30 Days)
50.5K
295.7K
Earning Date
10-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
14.65
N/A
EPS
0.95
N/A
Revenue
$88,952,000.00
$6,903,000.00
Revenue This Year
$4.05
N/A
Revenue Next Year
$0.38
$231.15
P/E Ratio
$24.86
N/A
Revenue Growth
14.87
N/A
52 Week Low
$14.94
$1.13
52 Week High
$24.17
$2.66

Technical Indicators

Market Signals
Indicator
ACR
CGEN
Relative Strength Index (RSI) 68.90 41.10
Support Level $22.74 $1.47
Resistance Level $23.99 $1.72
Average True Range (ATR) 0.90 0.09
MACD 0.19 -0.00
Stochastic Oscillator 89.43 10.00

Price Performance

Historical Comparison
ACR
CGEN

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: